EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-SA 4.0

cfDNA Integrity in Early Cancer Detection: A Review Article

Saad Abdul Kareem Mohammed, Adil Salim Owaid, Tariq Talal Abdaljabar, Esraa Ghazy Jabbar, Ali Saad Abdul Kareem Mohammed, Abdulla Saad Abdul Kareem Mohammed

The Journal of Iraqi Society of Pharmaceutical Sciences (ISSN 3136-9618) · 12.07.2026 · 1 (1) · 1-6

DOI: 10.68889/jisps.v1i1.a3 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Iraqi Society of Pharmaceutical Sciences (ISSN 3136-9618), online erschienen am 12.07.2026. Verfasst von Saad Abdul Kareem Mohammed und 5 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-SA 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Cell-free DNA (cfDNA) carries genetic and epigenetic information from its cells of origin. The integrity of cfDNA is the ratio of longer to shorter DNA fragments. It has emerged as a promising non-invasive biomarker for cancer diagnosis.

Objective

To synthesize current evidence on the diagnostic performance of cfDNA integrity in early cancer detection.

Methods

A comprehensive literature search was conducted in PubMed, Scopus, and Web of Science (2015–2026). Keywords related to cfDNA integrity, cancer, and diagnostics were used. Studies reporting quantitative integrity indices (e.g., ALU247/ALU115 ratio and LINE 1 fragments) and diagnostic accuracy metrics were included.

Results

A total of 98 studies were analyzed. The cell-free DNA (cfDNA) integrity index (cfDI) was elevated in patients with lung, colorectal, breast, hepatocellular, and ovarian cancer compared with healthy subjects. Sensitivity ranges from 55% to 88%, and specificity from 70% to 95%, depending on the cancer type and cutoff. Combination with other markers (e.g., protein biomarkers, DNA methylation panels) improves performance. However, pre-analytical variability, the lack of standardized integrity metrics, and inter-study heterogeneity limit the current clinical utility. Conclusions: cfDNA integrity holds considerable potential as an adjunctive tool for early cancer detection. Standardization of pre-analytical and analytical workflows is essential, along with large-scale prospective validation, before integration into routine clinical practice.

Zitieren

APA

Mohammed, S. A. K., Owaid, A. S., Abdaljabar, T. T., Jabbar, E. G., Mohammed, A. S. A. K., & Mohammed, A. S. A. K. (2026). cfDNA Integrity in Early Cancer Detection: A Review Article. The Journal of Iraqi Society of Pharmaceutical Sciences (ISSN 3136-9618), 1(1), 1-6. https://doi.org/10.68889/jisps.v1i1.a3

Vancouver

Mohammed SAK, Owaid AS, Abdaljabar TT, Jabbar EG, Mohammed ASAK, Mohammed ASAK. cfDNA Integrity in Early Cancer Detection: A Review Article. The Journal of Iraqi Society of Pharmaceutical Sciences (ISSN 3136-9618). 2026;1(1):1-6. doi:10.68889/jisps.v1i1.a3

BibTeX
@article{Mohammed2026,
  author = {Mohammed, Saad Abdul Kareem and Owaid, Adil Salim and Abdaljabar, Tariq Talal and Jabbar, Esraa Ghazy and Mohammed, Ali Saad Abdul Kareem and Mohammed, Abdulla Saad Abdul Kareem},
  title = {cfDNA Integrity in Early Cancer Detection: A Review Article},
  journal = {The Journal of Iraqi Society of Pharmaceutical Sciences (ISSN 3136-9618)},
  year = {2026},
  volume = {1},
  number = {1},
  pages = {1--6},
  doi = {10.68889/jisps.v1i1.a3}
}
Kostenlos starten →